Public deck
Acumen Pharmaceuticals (ABOS): the Alzheimer readout racing a cash clock
Acumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.
Public deck
Acumen's sabirnetug story is dominated by one late-2026 ALTITUDE-AD readout, a going-concern warning, and a cash runway that may not reach commercial proof.